{
    "id": 25262,
    "fullName": "SIRT1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SIRT1 positive indicates the presence of the SIRT1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 23411,
        "geneSymbol": "SIRT1",
        "terms": [
            "SIRT1",
            "SIR2",
            "SIR2alpha",
            "SIR2L1"
        ]
    },
    "variant": "positive",
    "createDate": "08/18/2016",
    "updateDate": "08/18/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SRT1460 and Taxol (paclitaxel) inhibited growth of human pancreatic cancer cell lines in culture, with greater efficacy compared to SRT1460 alone (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4157,
                "therapyName": "Paclitaxel + SRT1460",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6569,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SRT1720 inhibited growth and induced apoptosis of human pancreatic cancer cell lines in culture in a SIRT1-dependent manner, and inhibited tumor growth in pancreatic cancer cell line xenograft models (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4155,
                "therapyName": "SRT1720",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6570,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SRT1460 inhibited growth and induced apoptosis of human pancreatic cancer cell lines in a SIRT1-dependent manner, in culture (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4154,
                "therapyName": "SRT1460",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6575,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SRT1720 and Gemzar (gemcitabine) inhibited growth of human pancreatic cancer cell lines in culture, with greater efficacy compared to SRT1720 alone (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4159,
                "therapyName": "Gemcitabine + SRT1720",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SRT1720 and Taxol (paclitaxel) inhibited growth of human pancreatic cancer cell lines in culture, with increased efficacy over SRT1720 alone (PMID: 26655844).",
            "molecularProfile": {
                "id": 26069,
                "profileName": "SIRT1 positive"
            },
            "therapy": {
                "id": 4158,
                "therapyName": "Paclitaxel + SRT1720",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5700,
                    "pubMedId": 26655844,
                    "title": "SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26069,
            "profileName": "SIRT1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}